Kane Biotech Inc.
KNE.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.20K | 287.40K | 89.90K | 940.50K | 453.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.20K | 287.40K | 89.90K | 940.50K | 453.40K |
| Cost of Revenue | 53.10K | 257.90K | 152.20K | 530.80K | 190.00K |
| Gross Profit | -32.90K | 29.60K | -62.30K | 409.70K | 263.50K |
| SG&A Expenses | 101.00K | 656.70K | 232.90K | 723.50K | 715.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 219.30K | 1.10M | 672.40K | 1.39M | 1.26M |
| Operating Income | -199.10K | -809.00K | -582.50K | -448.20K | -806.00K |
| Income Before Tax | -251.90K | -849.00K | -773.60K | -497.60K | -888.70K |
| Income Tax Expenses | -- | -- | -936.00K | -- | -- |
| Earnings from Continuing Operations | -251.90K | -849.00K | 162.40K | -497.60K | -888.70K |
| Earnings from Discontinued Operations | -- | -- | -936.00K | 53.40K | 7.61M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.90K | -849.00K | -773.60K | -444.20K | 6.72M |
| EBIT | -199.10K | -809.00K | -582.50K | -448.20K | -806.00K |
| EBITDA | -165.60K | -797.00K | -559.00K | -414.20K | -766.30K |
| EPS Basic | 0.00 | -0.01 | -0.01 | 0.00 | 0.05 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.04 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 163.03M | 150.06M | 137.62M | 133.79M | 132.36M |
| Average Diluted Shares Outstanding | 180.51M | 150.06M | 137.62M | 133.79M | 158.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |